Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib

Published:2009-08 Issue:8 Volume:4 Page:994-1001
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Tsujino Kazuyuki,Kawaguchi Tomoya,Kubo Akihito,Aono Nana,Nakao Keiko,Koh Yasuhiro,Tachibana Kazunobu,Isa Shun-ichi,Takada Minoru,Kurata Takayasu

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference42 articles.

1. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III;El-Maraghi;J Clin Oncol,2008

2. Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success?;Chan;J Clin Oncol,2008

3. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

4. End points in advanced colon cancer clinical trials: a review and proposal;Allegra;J Clin Oncol,2007

5. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined;Saad;Ann Oncol,2009

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma;PLOS ONE;2022-05-12

2. Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy;Radiology and Oncology;2022-02-25

3. Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy;RADIOL ONCOL;2022

4. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12

5. Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art;Critical Reviews in Oncology/Hematology;2021-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3